A detailed history of Waypoint Capital Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Waypoint Capital Advisors, LLC holds 4,417 shares of ABBV stock, worth $900,493. This represents 0.21% of its overall portfolio holdings.

Number of Shares
4,417
Previous 4,257 3.76%
Holding current value
$900,493
Previous $730,000 19.45%
% of portfolio
0.21%
Previous 0.19%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$163.84 - $199.33 $26,214 - $31,892
160 Added 3.76%
4,417 $872,000
Q2 2024

Jul 25, 2024

BUY
$154.79 - $180.76 $24,302 - $28,379
157 Added 3.83%
4,257 $730,000
Q1 2024

Apr 30, 2024

BUY
$159.82 - $182.1 $10,548 - $12,018
66 Added 1.64%
4,100 $746,000
Q4 2023

Jan 22, 2024

SELL
$137.6 - $154.97 $14,998 - $16,891
-109 Reduced 2.63%
4,034 $625,000
Q3 2023

Oct 25, 2023

BUY
$133.59 - $154.65 $237,523 - $274,967
1,778 Added 75.18%
4,143 $617,000
Q2 2023

Jul 13, 2023

BUY
$132.51 - $164.9 $8,348 - $10,388
63 Added 2.74%
2,365 $318,000
Q1 2023

Apr 13, 2023

SELL
$144.61 - $166.54 $144 - $166
-1 Reduced 0.04%
2,302 $366,000
Q4 2022

Jan 23, 2023

BUY
$138.31 - $165.87 $1,521 - $1,824
11 Added 0.48%
2,303 $0
Q3 2022

Oct 17, 2022

BUY
$134.21 - $153.93 $134 - $153
1 Added 0.04%
2,292 $307,000
Q2 2022

Jul 18, 2022

SELL
$137.62 - $174.96 $5,504 - $6,998
-40 Reduced 1.72%
2,291 $351,000
Q1 2022

Apr 19, 2022

SELL
$131.98 - $163.75 $8,314 - $10,316
-63 Reduced 2.63%
2,331 $376,000
Q4 2021

Feb 07, 2022

BUY
$107.43 - $135.93 $257,187 - $325,416
2,394 New
2,394 $324,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $360B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Waypoint Capital Advisors, LLC Portfolio

Follow Waypoint Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Waypoint Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Waypoint Capital Advisors, LLC with notifications on news.